HGA
MRNA icon

Hobbs Group Advisors’s Moderna MRNA Stock Holding History

Hobbs Group Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20
Closed -$1.36K – 437
2024
Q3 		$1.36K Sell
20
-2,396
-99% -$220K ﹤0.01% 598
2024
Q2 		$287K Buy
+2,416
New +$306K 0.11% 119
2023
Q4 		$664K Buy
+6,674
New +$561K 0.3% 58

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Hobbs Group Advisors's MRNA Position: Q4 2024 in Review

Hobbs Group Advisors sold out of Moderna (MRNA) in Q4 2024, closing a stake of 20 shares — an estimated $1.36K sold.

Hobbs Group Advisors first reported a position in MRNA in Q4 2023 and held it in 3 quarters. The position peaked at $664K in Q4 2023. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Hobbs Group Advisors reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Hobbs Group Advisors sold 20 Moderna shares in Q4 2024, an estimated $1.36K.
  • Hobbs Group Advisors first reported a position in Moderna in Q4 2023 and held it in 3 quarters.
  • Hobbs Group Advisors's Moderna position peaked at $664K in Q4 2023.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Hobbs Group Advisors's 13F filing for Q4 2024, filed 12 Feb 2025.